Prevention of Acute Stroke and Transient Ischemic Attack (TIA) Order Set (Stroke Order Set 4)
|
|
- Ashlie Mills
- 7 years ago
- Views:
Transcription
1 Canadian Best Practice Recommendations for Stroke Care: All patients presenting to an emergency department or outpatient setting (family physician s office, ambulatory clinic, out-patient setting etc) with suspected stroke or transient ischemic attack must have an immediate clinical evaluation and investigations to establish the diagnosis, rule out stroke mimics, determine eligibility for thrombolytic therapy, and develop a plan for further management. Date of Stroke Prevention Assessment and Management Visit: Precautions Contact - Droplet- Airborne - Other: Stroke Symptom History Obtain and record stroke symptom history Most recent stroke event: Date of Onset/Last Seen as Normal Time: Determine type of stroke event and record: Acute Ischemic Stroke Subarachnoid hemorrhage Transient Ischemic Attack Intracerebral Hemorrhage Venous Sinus Thrombosis Other Signs and Symptoms (Describe): Stroke Severity and Focal Deficits Baseline assessment with standardized stroke scale National Institute of Health Stroke Scale (NIHSS) Baseline Score: or Canadian Neurologic Scale (CNS) Baseline Score: or Neurovital signs Diagnostic Testing Neuroimaging CT Head Non Contrast (per Stroke Protocol Urgency: STAT Within 24 hours Within week(s); *Date of scan: (dd/mm/yy) Time of scan start (hh:min) or Diffusion Weighted MRI (per Stroke Protocol) Urgency: STAT Within 24 hours Within week(s * Date of scan: (dd/mm/yy) Time of scan start (hh:min) (dd/mm/yy) (dd/mm/yy) *If scan booked for a future date, indicate the booked appointment time. SIGNATURE V1 Page 1 of 6
2 Diagnostic Cardiac 12-lead ECG Record presence of Atrial Fibrillation or Flutter Yes No Holter Monitor Transthoracic Echocardiogram Transesophageal Echocardiogram Include Bubble Study Cardiac CT (per Stroke Protocol) Carotid Imaging Cardiac MRI (per Stroke Protocol) Carotid ultrasound Dopplers Urgency: STAT Within 24 hours CT Angiogram Urgency: STAT Within 24 hours MR Angiogram Urgency: STAT Within 24 hours Date of Carotid Imaging: (dd/mm/yy) Time of scan start (hh:min) CXR PA + Lateral Other: Consults Consults to Physicians EEG Stroke Prevention Clinic Appointment booked: (Date) Stroke Neurologist/Stroke Specialist Appointment booked: (Date) Neurosurgeon Appointment booked: (Date) Vascular Surgeon Appointment booked: (Date) Other: Appointment booked: (Date) Consults to Interdisciplinary Stroke Team Members/External Services Dietitian Pharmacist Psychologist Home Care Services Physical Therapist Speech Language Pathologist Occupational Therapist Physiatrist Social Worker Palliative Care Specialist/Team Psychiatrist Other: Vital Signs and Assessment Baseline temperature, heart rate, blood pressure, respiratory rate Actual Weight kg or Estimated Weight kg Height: cm Body Mass Index. Calculated: kg/metre 2 Waist Circumference cm SpO 2 via pulse oximetry Maintain SpO 2 at % SIGNATURE V1 Page 2 of 6
3 Vital Signs and Assessment Continued Assessments Baseline swallow assessment Date: Record Result: Normal Abnormal If swallow assessment abnormal, initiate referral to speech language pathologist for further assessment Baseline Functional Assessment Alpha-FIM Modified Rankin Score Other Baseline Cognitive Assessment: Assessment Tool (e.g. MOCA): Score: Baseline Depression Screen: Screening Tool (e.g. HAD, PDQ): Score: Baseline Fitness to Drive Assessment (if applicable): Tool: Outcome: Baseline Sleep Apnea screening (if applicable): Tool: Outcome: Lab Investigations CBC PTT INR Capillary Blood Glucose STAT Electrolytes (Na, K, Cl) Creatinine Glucose BUN CK Troponin Ca, Mg ` LDH Hgb A1C Fasting Glucose Fasting Lipid Profile (HDL, LDL, Total Cholesterol, Triglycerides) ALT, ALP, Bilirubin AST TSH If female less than 50 years of age, β HCG or urine pregnancy test ABG Coagulopathy screens: Anticardiolipin (Antiphospholipid) Antibody Lupus Anticoagulant Protein S Protein C Prothrombin Gene Mutation Factor V Leiden Mutation/APC resistance PNH screen Fasting serum homocysteine Antithrombin III ESR C-Reactive Protein (CRP) Antinuclear antibody (ANA) Syphilis Screen Sickle Cell Screen Blood C + S x 3 (endocarditis cultures) Urine C + S Urine R + M Additional Lab tests: Test: Test: Test: SIGNATURE V1 Page 3 of 6
4 Antiplatelet Agents NA No anticoagulants, No antithrombotics until CT or MRI completed and hemorrhage ruled out Acute ASA loading Dose: order at least 160 mg of acetylsalicylic acid (ASA) immediately as a one time loading dose after brain imaging has excluded intracranial hemorrhage acetylsalicylic acid : mg PO enteric coated acetylsalicylic acid (ECASA) one-time loading dose THEN enteric coated acetylsalicylic acid (ECASA) clopidogrel 300 mg PO loading dose THEN clopidogrel 75 mg PO daily mg PO daily ( mg) mg PO ( mg), Extended-release dipyridamole 200 mg/acetylsalicylic acid 25 mg (Aggrenox) 1 capsule PO BID (MD may consider ordering a loading dose of acetylsalicylic acid mg first) Other antithrombotic: (Medication, dose, route, frequency) Note: Canadian Best Practice Recommendations for Stroke Care Recommendation: Short-term concurrent use of acetylsalicylic acid and clopidogrel (up to 90 days) has not shown an increased risk of bleeding; however, longer-term use is not recommended for secondary stroke prevention, unless there is an alternate indication (e.g., drug-eluting carotid artery stent requiring dual antiplatelet therapy), due to an increased risk of bruising and bleeding. Anticoagulant Agents for Patients with Atrial Fibrillation or Other Indication Indication for anticoagulants: No anticoagulants until CT or MRI completed and hemorrhage ruled out Assess baseline creatinine clearance prior to anticoagulant administration, then annually In patients with atrial fibrillation, begin anticoagulation for secondary stroke prevention. apixaban dabigatran rivaroxaban mg PO BID (when available for use in Canada) mg PO BID mg PO daily warfarin loading dose of mg PO daily for days THEN warfarin mg PO daily for days THEN, when therapeutic range achieved, start warfarin maintenance dose: Measure INR on mg PO daily NA days (list days and frequency of INR monitoring) Therapeutic goal on warfarin is an INR between 2.0 and 3.0 (aim for an INR of 2.5) more than 70% of the time, or other therapeutic range goal: Concomitant antiplatelet therapy with oral anticoagulation is not recommended in patients with atrial fibrillation unless there is a specific medical indication such as a coronary stent SIGNATURE V1 Page 4 of 6
5 Blood Pressure Management Recommend following the Canadian Hypertension Education program (CHEP) hypertension management protocols Glycemic Management for Patients with Diabetics Recommend following the Canadian Diabetes Association diabetes management protocols Lipid Management Recommend following the Canadian Cardiovascular Society Dyslipidemia management protocols Nausea Management dimenhydrinate mg PO/NG/IV/PR q4h PRN (use lowest possible for effect for elderly/frail) dimenhydrinate mg PO/NG/IV/PR/IM q4h PRN (use lowest possible for effect for elderly/frail) Pain Management acetaminophen Smoking Cessation mg PO/NG/PR q4h PRN for pain Dose/Route/Frequency: Determine smoking status, and if smoker determine readiness to attempt to quit Referral to Smoking Cessation Program/Specialist: (Name) Appointment Booked: Smoking Cessation Medication* Smoking Cessation Medication* (Date, Time) * Canadian Best Practice Recommendations for Stroke Care : The three classes of pharmacological agents that should be considered as first-line therapy for smoking cessation are nicotine replacement therapy, bupropion, and varenicline (Smoking Cessation recommendation 2.9, Update 2012) SIGNATURE V1 Page 5 of 6
6 Other Medications Discharge/Transition Plan Reason, Reason, Reason, Reason, Provide patient and family education and skills training as required regarding: Stroke signs and symptoms and appropriate actions to take Contact numbers for EMS, neurologist, stroke team, other healthcare professionals Risk Factor modification assist with development/update of an individualized plan Activity levels, activities of daily living Safety and avoidance of falls and injury Rehabilitation Driving Sexual Activity Community Support Group resources Other Provide patient and family with written summary of prevention plan at end of ambulatory care visit (ED, prevention clinic, family physician s office, other community setting) Disposition Admit patient to Emergency Department Facility: Admit patient to Inpatient Facility Facility: Or Refer patient to Stroke Prevention Clinic or Service SPC: Appointment Date: Appointment Time: Refer patient to Home Care services Refer patient to outpatient or community-based rehabilitation for assessment and treatment Facility: Appointment Date: Appointment Time: Follow-up with Family Physician (Name) Send consult letter to Family Physician within 72 hours Other Follow-up Appointments: Name: Specialty: SIGNATURE V1 Page 6 of 6
PHYSICIAN SIGNATURE DATE TIME DRUG ALLERGIES WT: KG
MED Hospitalist Stroke-TIA Vital Signs Vital Signs Q4H (DEF)* Q2H Q1H Vital Signs Orthostatic Activity Activity Bedrest, for 12 hours then Up ad lib (DEF)* Bedrest, for 24 hours then Up ad lib Up Ad Lib
More informationREMINDER: Please ensure all stroke and TIA patients admitted to hospital are designated as "Stroke Service" in Cerner.
ACUTE STROKE CLINICAL PATHWAY QEH/HH PCH KCMH Souris Western Stewart Memorial O'Leary PATIENT ID INCLUSION CRITERIA* All patients admitted to hosptial with a suspected diagnosis of acute ischemic stroke
More informationChronic Obstructive Pulmonary Disease (COPD) Admission Order Set
Patient Name: PHN: Page 1/1 Admit to Dr: Notified Consult: Dr: Family Dr: Precautions: Contact Droplet Enhanced Droplet Airborne - Reason: _ Code Status: Full Resuscitation or Consults: Reason: Dietician
More informationAppendix L: HQO Year 1 Implementation Priorities
Appendix L: HQO Year 1 Implementation Priorities Chronic Obstructive Pulmonary Disease (Source: COPD Chairs) Non-Invasive Positive Pressure Ventilation Early Ambulation If possible, seek patient preferences
More informationPHYSICIAN ORDERS TRANSIENT ISCHEMIC ATTACK (TIA) OBSERVATION
SCREENING- ABCD-2 Score The ABCD2 score is a risk assessment tool designed to improve the prediction of short-term stroke risk after a transient ischemic attack (TIA). Higher ABCD2 scores are associated
More informationSurvey of Canadian Physicians Use of anti-thrombotic therapy for Atrial Fibrillation
Survey of Canadian Physicians Use of anti-thrombotic therapy for Atrial Fibrillation On the following pages are a number of questions asking about the conditions under which you would prescribe anticoagulation
More informationAHA/ASA Ischemic Stroke Performance Measures
AHA/ASA Ischemic Stroke Performance Measures 1. Venous thromboembolism prophylaxis Percentage of patients with ischemic stroke who receive venous thromboembolism prophylaxis Numerator Hospital day 0 or
More informationA Patient s Guide to Antithrombotic Therapy in Atrial Fibrillation
Patient s Guide to Antithrombotic Therapy in Atrial Fibrillation A Patient s Guide to Antithrombotic Therapy in Atrial Fibrillation PATIENT EDUCATION GUIDE What is atrial fibrillation? Atrial fibrillation
More informationNew Treatments for Stroke Prevention in Atrial Fibrillation. John C. Andrefsky, MD, FAHA NEOMED Internal Medicine Review course May 5 th, 2013
New Treatments for Stroke Prevention in Atrial Fibrillation John C. Andrefsky, MD, FAHA NEOMED Internal Medicine Review course May 5 th, 2013 Classification Paroxysmal atrial fibrillation (AF) Last < 7
More informationStroke: Major Public Health Burden. Stroke: Major Public Health Burden. Stroke: Major Public Health Burden 5/21/2012
Faculty Prevention Sharon Ewer, RN, BSN, CNRN Stroke Program Coordinator Baptist Health Montgomery, Alabama Satellite Conference and Live Webcast Monday, May 21, 2012 2:00 4:00 p.m. Central Time Produced
More informationSTROKE PREVENTION IN ATRIAL FIBRILLATION. TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: ABBREVIATIONS: BACKGROUND:
STROKE PREVENTION IN ATRIAL FIBRILLATION TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: To guide clinicians in the selection of antithrombotic therapy for the secondary prevention
More informationThe author has no disclosures
Mary Bradbury, PharmD, BCPS Clinical Pharmacy Specialist, Cardiac Surgery September 18, 2012 Mary.bradbury@inova.org This presentation will discuss unlabeled and investigational use of products The author
More informationNovel oral anticoagulant (NOAC) for stroke prevention in atrial fibrillation Special situations
Novel oral anticoagulant (NOAC) for stroke prevention in atrial fibrillation Special situations Dardo E. Ferrara MD Cardiac Electrophysiology North Cascade Cardiology PeaceHealth Medical Group Which anticoagulant
More informationSTROKE PREVENTION IN ATRIAL FIBRILLATION
STROKE PREVENTION IN ATRIAL FIBRILLATION OBJECTIVE: To guide clinicians in the selection of antithrombotic therapy for the secondary prevention of ischemic stroke and arterial thromboembolism in patients
More informationSecondary Stroke Prevention Luke Bradbury, MD 10/4/14 Fall WAPA Conferfence
Guidelines Secondary Stroke Prevention Luke Bradbury, MD 10/4/14 Fall WAPA Conferfence Stroke/TIA Nearly 700,000 ischemic strokes and 240,000 TIAs every year in the United States Currently, the risk for
More informationIschemic Stroke Clinical Pathway
Ischemic Stroke Clinical Pathway Legal Treatments Advance Directives Refer to the ED Stroke Algorithm Patient exam: review history, Check VS/Neuro every 2 hour or per M.D. order Strict I & O s Cardiac
More informationDorset Cardiac Centre
P a g e 1 Dorset Cardiac Centre Patients with Atrial Fibrillation/Flutter undergoing DC Cardioversion or Ablation procedures- Guidelines for Novel Oral Anti-coagulants (NOACS) licensed for this use February
More informationNew in Atrial Fibrillation
New in Atrial Fibrillation September 2011 Stroke prevention more options Rhythm Control -drugs - alternatives to drugs; ablation Rate Control - pace + ablate A-FIB Dell Stroke Risk AFib Two Principles
More informationLet s talk about: Stroke
Let s talk about: Stroke February 20 th 2013 Laura Wilson Christine Stables Questions 1. Why is knowing about stroke important? 2. What exactly is a stroke and what are the symptoms? 3. What should I do
More informationTreating AF: The Newest Recommendations. CardioCase presentation. Ethel s Case. Wayne Warnica, MD, FACC, FACP, FRCPC
Treating AF: The Newest Recommendations Wayne Warnica, MD, FACC, FACP, FRCPC CardioCase presentation Ethel s Case Ethel, 73, presents with rapid heart beating and mild chest discomfort. In the ED, ECG
More informationApproved: Acute Stroke Ready Hospital Advanced Certification Program
Approved: Acute Stroke Ready Hospital Advanced Certification Program The Joint Commission recently developed a new Disease- Specific Care Advanced Certification program for Acute Stroke Ready Hospitals
More informationACUTE STROKE REGISTRY (NJASR) VERSION 2.0) (Continued)
New Jersey Department of Health ACUTE STROKE REGISTRY (NJASR) VERSION 2.0 A. DEMOGRAPHIC DATA *Hospital Type (1): 1=Primary 2=Comprehensive 3=Other *Hospital Code (2): *Hospital Transferred From Code (3):
More informationDERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) MANAGEMENT of Atrial Fibrillation (AF)
DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) MANAGEMENT of Atrial Fibrillation (AF) Key priorities Identification and diagnosis Treatment for persistent AF Treatment for permanent AF Antithrombotic
More informationStroke Care First week
Stroke Care First week Florence Nightingale (1820 1910) Stroke Unit Dedicated personnel trained in stroke management Stepwise guidelines supported by explicit checklists Continuous monitoring available
More informationMedical Management of Ischemic Stroke: An Update. Siddharth Sehgal, MD Medical Director, TMH Neuroscience Center
Medical Management of Ischemic Stroke: An Update Siddharth Sehgal, MD Medical Director, TMH Neuroscience Center Objectives Diagnostic evaluation and management of acute ischemic stroke. Inpatient management
More informationAnticoagulants in Atrial Fibrillation
Anticoagulants in Atrial Fibrillation Starting and Stopping Them Safely Carmine D Amico, D.O. Overview Learning objectives Introduction Basic concepts Treatment strategy & options Summary 1 Learning objectives
More informationOptimizing Anticoagulation Selection for Your Patient. C. Andrew Brian MD, FACC NCVH 2015
Optimizing Anticoagulation Selection for Your Patient C. Andrew Brian MD, FACC NCVH 2015 Who Needs to Be Anticoagulated and What is the Patient s Risk? 1. Atrial Fibrillation ( nonvalvular ) 2. What regimen
More informationDVT/PE Management with Rivaroxaban (Xarelto)
DVT/PE Management with Rivaroxaban (Xarelto) Rivaroxaban is FDA approved for the acute treatment of DVT and PE and reduction in risk of recurrence of DVT and PE. FDA approved indications: Non valvular
More informationTHE INTERNET STROKE CENTER PRESENTATIONS AND DISCUSSIONS ON STROKE MANAGEMENT
THE INTERNET STROKE CENTER PRESENTATIONS AND DISCUSSIONS ON STROKE MANAGEMENT Stroke Prevention in Atrial Fibrillation Gregory Albers, M.D. Director Stanford Stroke Center Professor of Neurology and Neurological
More informationAntiplatelet and Antithrombotics From clinical trials to guidelines
Antiplatelet and Antithrombotics From clinical trials to guidelines Ashraf Reda, MD, FESC Prof and head of Cardiology Dep. Menofiya University Preisedent of EGYBAC Chairman of WGLVR One of the big stories
More informationALBERTA PROVINCIAL STROKE STRATEGY (APSS)
ALBERTA PROVINCIAL STROKE STRATEGY (APSS) Stroke Systems of Care Key Components APSS Pillar Recommendations March 28, 2007 1 The following is a summary of the key components and APSS Pillar recommendations
More informationAntiplatelet and Antithrombotic Therapy. Dr Curry Grant Stroke Prevention Clinic Quinte Health Care
Antiplatelet and Antithrombotic Therapy Dr Curry Grant Stroke Prevention Clinic Quinte Health Care Disclosure of Potential for Conflict of Interest Dr. F.C. Grant Atrial Fibrillation FINANCIAL DISCLOSURE:
More informationLevel III Stroke Center Data Collection Requirements
Who? Level III Stroke Center Data Collection Requirements All LERN Level III Stroke Centers. LERN Level I and II Stroke Centers have reporting requirements to The Joint Commission or other Board approved
More informationKevin Saunders MD CCFP Rivergrove Medical Clinic Wellness Institute @ SOGH April 17 2013
Kevin Saunders MD CCFP Rivergrove Medical Clinic Wellness Institute @ SOGH April 17 2013 Family physician with Rivergrove Medical Clinic Practice in the north end since 1985 Medical Director of the Wellness
More informationAcute Ischemic Stroke with tpa
Admission/Condition/Diagnosis Admission: Admitting Physician Attending Physician Assign to Inpatient Status Transfer to Level of Care: Physician MUST document in notes the risk, severity, and skilled nursing
More information9/5/14. Objectives. Atrial Fibrillation (AF)
Novel Anticoagulation for Prevention of Stroke in Patients with Atrial Fibrillation Objectives 1. Review current evidence on use of warfarin in individuals with atrial fibrillation 2. Compare the three
More informationNICE TA 275: Apixaban for the prevention of stroke and systemic embolism in people with non-valvular atrial fibrillation
Service Notification in response to DHSSPS endorsed NICE Technology Appraisals NICE TA 275: Apixaban for the prevention of stroke and systemic embolism in people with non-valvular atrial fibrillation 1
More informationRivaroxaban: Amber Drug Guidance for the prevention of stroke and systemic embolism in patients with non-valvular AF
Leeds Rivaroxaban: Amber Drug Guidance for the prevention of stroke and systemic embolism in patients with non-valvular AF Amber Drug Level 3 (amber drug with monitoring requirements) We have started your
More informationAtrial fibrillation: medicines to help reduce your risk of a stroke what are the options?
Patient decision aid Atrial fibrillation: medicines to help reduce your risk of a stroke what are the options? http://guidance.nice.org.uk/cg180/patientdecisionaid/pdf/english Published: June 2014 About
More informationVascular Risk Reduction: Addressing Vascular Risk
Vascular Risk Reduction: Addressing Vascular Risk Vascular Risk Reduction (VRR) Welcome! Presentation & Activities Focus: Managing known risk factors for vascular disease. Engage, collaborate and have
More informationPRESCRIBING FOR SMOKING CESSATION. (Adapted from the Self-Limiting Conditions Independent Study Program for Manitoba Pharmacists)
PRESCRIBING FOR SMOKING CESSATION (Adapted from the Self-Limiting Conditions Independent Study Program for Manitoba Pharmacists) Acknowledgements The Self-Limiting Conditions Independent Study Program
More informationAll patients presenting to the Emergency Department with symptoms suggestive of
APPENDIX: Online Data Supplements Clinical Trial Inclusion and Exclusion Criteria All patients presenting to the Emergency Department with symptoms suggestive of acute coronary syndrome (ACS) were screened
More informationMISSING DATA ANALYSIS AMONG PATIENTS IN THE PINNACLE REGISTRY
MISSING DATA ANALYSIS AMONG PATIENTS IN THE PINNACLE REGISTRY In order to improve the efficiency of PINNACLE Registry data analytics, a missing data analysis has been conducted on PINNACLE Registry data
More informationRx Updates New Guidelines, New Medications What You Need to Know
Rx Updates New Guidelines, New Medications What You Need to Know Maria Pruchnicki, PharmD, BCPS, BCACP, CLS Associate Professor of Clinical Pharmacy OSU College of Pharmacy Background scope and impact
More informationORAL ANTICOAGULANTS - RIVAROXABAN (XARELTO) FOR ATRIAL FIBRILLATION
ORAL ANTICOAGULANTS - RIVAROXABAN (XARELTO) FOR ATRIAL FIBRILLATION Information Leaflet Your Health. Our Priority. Page 2 of 6 What Are Anticoagulants And What Do They Do? This information leaflet has
More informationGuidelines and Protocols
TITLE: HEAD TRAUMA PURPOSE: To provide guidelines for rapid, accurate assessment of the head and intracranial structures for traumatic injury and to plan and implement appropriate interventions for identified
More informationPlanning: Patient Goals and Expected Outcomes The patient will: Remain free of unusual bleeding Maintain effective tissue perfusion Implementation
Obtain complete heath history including allergies, drug history and possible drug Assess baseline coagulation studies and CBC Assess for history of bleeding disorders, GI bleeding, cerebral bleed, recent
More informationThe Clinical Evaluation of the Comatose Patient in the Emergency Department
The Clinical Evaluation of the Comatose Patient in the Emergency Department patients with altered mental status (AMS) and coma. treat patients who present to the Emergency Department with altered mental
More informationDabigatran (Pradaxa) Guidelines
Dabigatran (Pradaxa) Guidelines Dabigatran is a new anticoagulant for reducing the risk of stroke in patients with atrial fibrillation. Dabigatran is a direct thrombin inhibitor, similar to warfarin, without
More informationEMS Management of Stroke. Deaver Shattuck, M.D. Brian Wiseman, M.D. Keith Woodward, M.D.
EMS Management of Stroke Deaver Shattuck, M.D. Brian Wiseman, M.D. Keith Woodward, M.D. Financial Disclosure: No relevant financial relationship exists Working Together to End Stroke Formed in 2013 Identified
More informationAtrial Fibrillation, Chronic - Antithrombotic Treatment - OBSOLETE
Atrial Fibrillation, Chronic - Antithrombotic Treatment - OBSOLETE Clinical practice guidelines serve as an educational reference, and do not supersede the clinical judgment of the treating physician with
More informationEvaluating ED Patients with Transient Ischemic Attack: Inpatient vs. Outpatient Strategies
Evaluating ED Patients with Transient Ischemic Attack: Inpatient vs. Outpatient Strategies Michael A. Ross MD FACEP Associate Professor of Emergency Medicine Wayne State University School of Medicine Detroit
More informationDabigatran: Amber Drug Guidance for the prevention of stroke and systemic embolism in patients with non-valvular AF
Leeds Dabigatran: Amber Drug Guidance for the prevention of stroke and systemic embolism in patients with non-valvular AF Amber Drug Level 3 (amber drug with monitoring requirements) We have started your
More informationCritical Bleeding Reversal Protocol
Critical Bleeding Reversal Protocol Coagulopathy, either drug related or multifactorial, is a major contributing factor to bleeding related mortality in a variety of clinical settings. Standard therapy
More information2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: CLAIMS, REGISTRY
Measure #326 (NQF 1525): Atrial Fibrillation and Atrial Flutter: Chronic Anticoagulation Therapy National Quality Strategy Domain: Effective Clinical Care 2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: CLAIMS,
More informationWhat do these stories illustrate about ER/ALC issue?
What do these stories illustrate about ER/ALC issue? Maximizing the Impact of Rehab on Provincial Priority Issues Mark Bayley, MD, FRCPC Medical Director, Neuro Rehabilitation Program, Toronto Rehab and
More informationThe Anti coagulated Patient: The Cardiologist s View. February 28, 2015
The Anti coagulated Patient: The Cardiologist s View February 28, 2015 Conflicts Dr. McMurtry has no conflicts to disclose. CanMeds Medical Expert (as Medical Experts, physicians integrate all of the CanMEDS
More informationPROTOCOL TITLE: Ambulatory Initiation and Management of Warfarin for Adults
PROTOCOL NUMBER: 7 PROTOCOL TITLE: Ambulatory Initiation and Management of Warfarin for Adults THIS PROTOCOL APPLIES TO: UW Health Clinics: all adult outpatients with an active order for warfarin TARGET
More informationPrimary Stroke Certification
Primary Stroke Certification Clinical Standards A Program of the American Osteopathic Association 142 East Ontario Street Chicago, IL 60611-2864 GOVERNANCE Strategic Direction GOVERNANCE PLAN 01.00.01
More information9/28/15. Dabigatran. Rivaroxaban. Apixaban. Edoxaban. From the AC Forum Centers of Excellence website: Dabigatran, Rivaroxaban, & Apixaban
Identify the FDA approved direct oral anticoagulants (DOACs) Linda Kelly, PharmD, PhC, CACP Presbyterian Healthcare Services Distinguish the differences in the dosing of DOACs for various indications Describe
More informationSTATEMENT OF STANDARD
OHSU HEALTH CARE SYSTEM PRACTICE STANDARD Acute Stroke Practice Standard for the Emergency Department (includes ischemic stroke, TIAs, intracerebral hemorrhage, and non-subarachnoid hemorrhage), PS 01.11
More informationEvidence-Based Secondary Stroke Prevention and Adherence to Guidelines
Evidence-Based Secondary Stroke Prevention and Adherence to Guidelines Mitchell S.V. Elkind, MD, MS Associate Professor of Neurology Columbia University New York, NY Presenter Disclosure Information Mitchell
More informationUse of Antithrombotic Agents In The Presence Of Neuraxial Anesthesia
Use of Antithrombotic Agents In The Presence Of Neuraxial Anesthesia Insertion, removal or presence of a catheter in selected sites can place a patient who is antithrombotic agent at risk for a local bleeding
More informationRR 0.88 (95% CI: 0.77 1.00) P=0.051 (superiority) 3.75
ALL-CAUSE MORTALITY RR 0.88 (95% CI: 0.77 1.00) P=0.051 (superiority) Rate per year (%) 5.0 4.0 3.0 2.0 1.0 0 3.64 D150 mg BID 3.75 D110 mg BID RR 0.91 (95% CI: 0.80 1.03) P=0.13 (superiority) 4.13 Warfarin
More informationWhat s New in Stroke?
5 th McMaster University Review Course in INTERNAL MEDICINE What s New in Stroke? Robert Hart, M.D. HHS / McMaster Stroke Program Department of Medicine (Neurology) McMaster University Hamilton, Ontario
More informationMarilyn Borkgren-Okonek, APN, CCNS, RN, MS Suburban Lung Associates, S.C. Elk Grove Village, IL
Marilyn Borkgren-Okonek, APN, CCNS, RN, MS Suburban Lung Associates, S.C. Elk Grove Village, IL www.goldcopd.com GLOBAL INITIATIVE FOR CHRONIC OBSTRUCTIVE LUNG DISEASE GLOBAL STRATEGY FOR DIAGNOSIS, MANAGEMENT
More informationF A S T. Transient ischaemic attack (TIA)
Stroke Helpline: 0303 3033 100 Website: stroke.org.uk Transient ischaemic attack (TIA) A transient ischaemic attack (TIA) is similar to a stroke, but the symptoms do not last as long. However, it should
More informationCOMPARISON OF NEW ORAL ANTICOAGULANTS AND FREQUENTLY- ASKED QUESTIONS FROM PATIENTS. TARGET AUDIENCE: All Canadian health care professionals.
COMPARISON OF NEW ORAL ANTICOAGULANTS AND FREQUENTLY- ASKED QUESTIONS FROM PATIENTS AND PHYSICIANS TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVES: To provide a comparison of the new
More informationHERTFORDSHIRE MEDICINES MANAGEMENT COMMITTEE (HMMC) RIVAROXABAN RECOMMENDED see specific recommendations for licensed indications below
Name: generic (trade) Rivaroxaban (Xarelto ) HERTFORDSHIRE MEDICINES MANAGEMENT COMMITTEE (HMMC) RIVAROXABAN RECOMMENDED see specific recommendations for licensed indications below What it is Indications
More informationAcute Myocardial Infarction (the formulary thrombolytic for AMI at AAMC is TNK, please see the TNK monograph in this manual for information)
ANNE ARUNDEL MEDICAL CENTER CRITICAL CARE MEDICATION MANUAL DEPARTMENT OF NURSING AND PHARMACY Guidelines for Use of Intravenous Alteplase (Tissue Plasminogen Activator (t-pa)), Activase in the Treatment
More informationA Patient s Guide to Primary and Secondary Prevention of Cardiovascular Disease Using Blood-Thinning (Anticoagulant) Drugs
A Patient s Guide to Primary and Secondary Prevention of PATIENT EDUCATION GUIDE What Is Cardiovascular Disease? Cardiovascular disease (CVD) is a broad term that covers any disease of the heart and circulatory
More informationPatient education for stroke prevention after a TIA
RMH Comprehensive Stroke Centre Louise Weir Stroke Nurse Practitioner Candidate- The Royal Melbourne Hospital Patient education for stroke prevention after a TIA ANNA Stroke Seminar 2010 Objectives TIA
More informationGENERAL HEART DISEASE KNOW THE FACTS
GENERAL HEART DISEASE KNOW THE FACTS WHAT IS Heart disease is a broad term meaning any disease affecting the heart. It is commonly used to refer to coronary heart disease (CHD), a more specific term to
More informationINTRODUCTION Thrombophilia deep vein thrombosis DVT pulmonary embolism PE inherited thrombophilia
INTRODUCTION Thrombophilia (Hypercoagulability) is a condition in which a person forms blood clots more than normal. Blood clots may occur in the arms or legs (e.g., deep vein thrombosis DVT), the lungs
More informationINTRODUCTION Thrombophilia deep vein thrombosis DVT pulmonary embolism PE inherited thrombophilia
INTRODUCTION Thrombophilia (Hypercoagulability) is a condition in which a person forms blood clots more than normal. Blood clots may occur in the arms or legs (e.g., deep vein thrombosis DVT), the lungs
More informationWhat to Know About. Atrial Fibrillation
Atrial Fibrillation What to Know About Atrial Fibrillation Understanding Afib Atrial fibrillation, or Afib, is a condition in which the heart beats irregularly speeding up or slowing down, or beating too
More informationPhysician and other health professional services
O n l i n e A p p e n d i x e s 4 Physician and other health professional services 4-A O n l i n e A p p e n d i x Access to physician and other health professional services 4 a1 Access to physician care
More informationUHS CLINICAL CARE COLLABORATION: Outpatient & Inpatient
Guidelines for Anticoagulation Initiation and Management Y2014 UHS CLINICAL CARE COLLABORATION: Outpatient & Inpatient Topic Page Number MEDICATION FLOW AND PATIENT FLOW... 2 AND 3 PARENTERAL ANTICOAGULANTS...
More information3/25/14. To Clot or Not What s New In Anticoagulation? Clotting Cascade. Anticoagulant drug targets. Anita Ralstin, MS CNS CNP. Heparin.
To Clot or Not What s New In Anticoagulation? Anita Ralstin, MS CNS CNP 1 Clotting Cascade 2 Anticoagulant drug targets Heparin XI VIII IX V X VII LMWH II Warfarin Fibrin clot 1 Who Needs Anticoagulation
More informationProvision of Intravenous EDTA Chelation as a Complementary and Alternative Medicine
Provision of Intravenous EDTA Chelation as a Complementary and Alternative Medicine Guideline Updated: August 2010 Replaced: November 1998 To serve the public and guide the medical profession EDTA Chelation
More informationCDEC FINAL RECOMMENDATION
CDEC FINAL RECOMMENDATION RIVAROXABAN (Xarelto Bayer Inc.) Indication: Stroke Prevention in Atrial Fibrillation This recommendation supersedes the Canadian Drug Expert Committee (CDEC) recommendation for
More informationACUTE STROKE UNIT ORIENTATION
ACUTE STROKE UNIT ORIENTATION 2014 TEACHING YOUR STROKE PATIENTS ABOUT THEIR MEDICATION Please refer to Module 8: Secondary Stroke Prevention for additional information Blood Pressure Medication Angiotensin
More informationQuiz 4 Arrhythmias summary statistics and question answers
1 Quiz 4 Arrhythmias summary statistics and question answers The correct answers to questions are indicated by *. All students were awarded 2 points for question #2 due to no appropriate responses for
More informationFOR THE PREVENTION OF ATRIAL FIBRILLATION RELATED STROKE
www.bpac.org.nz keyword: warfarinaspirin FOR THE PREVENTION OF ATRIAL FIBRILLATION RELATED STROKE Key Concepts In atrial fibrillation (AF) warfarin is more effective than aspirin for stroke prevention.
More informationNHS FORTH VALLEY Rivaroxaban for Stroke Prevention in Atrial Fibrillation
NHS FORTH VALLEY Rivaroxaban for Stroke Prevention in Atrial Fibrillation Date of First Issue 06/06/2012 Approved 06/06/2012 Current Issue Date 29/10/2014 Review Date 29/10/2016 Version 1.4 EQIA Yes 01/06/2012
More informationBayer Pharma AG 13342 Berlin Germany Tel. +49 30 468-1111 www.bayerpharma.com. News Release. Not intended for U.S. and UK Media
News Release Not intended for U.S. and UK Media Bayer Pharma AG 13342 Berlin Germany Tel. +49 30 468-1111 www.bayerpharma.com Bayer Forms Collaboration with Academic and Governmental Institutions for Rivaroxaban
More informationPsychiatrists and Reporting on Meaningful Use Stage 1. August 6, 2012
Psychiatrists and Reporting on Meaningful Use Stage 1 August 6, 2012 Quick Overview Functional Measures Providers (tracked by NPI) must report on 15 core objectives and associated measures and 5 objectives
More informationJHS Stroke Program. 2016 JHS Annual Mandatory Education
JHS Stroke Program 2016 JHS Annual Mandatory Education Learner Objectives At the conclusion of this module learners will be able to: State the definition of stroke Discuss the pathophysiology of stroke
More informationWhat You Need to KnowWhen Taking Anticoagulation Medicine
What You Need to KnowWhen Taking Anticoagulation Medicine What are anticoagulant medicines? Anticoagulant medicines are a group of medicines that inhibit blood clotting, helping to prevent blood clots.
More informationMEDICAL NUTRITION THERAPY (MNT) CLINICAL NUTRITION THERAPY Service Time CPT Code
MEDICAL NUTRITION THERAPY (MNT) CLINICAL NUTRITION THERAPY Service Time CPT Code Initial Assessment And Intervention This Code Can Be Used Only Once A Year For First Appointment Medical Nutrition Therapy
More informationAppendix C Factors to consider when choosing between anticoagulant options and FAQs
Appendix C Factors to consider when choosing between anticoagulant options and FAQs Choice of anticoagulant for non-valvular* atrial fibrillation: Clinical decision aid Patients should already be screened
More informationHeart Center Packages
Heart Center Packages For more information and appointments, Please contact The Heart Center of Excellence at the American Hospital Dubai Tel: +971-4-377-6571 Email: heartcenter@ahdubai.com www.ahdubai.com
More informationMaking the Case for CPG s Jean Luciano, MSN, RN, CNRN, SCRN, CRNP, FAHA Claranne Mathiesen, MSN, RN, CNRN, SCRN, FAHA
Making the Case for CPG s Jean Luciano, MSN, RN, CNRN, SCRN, CRNP, FAHA Claranne Mathiesen, MSN, RN, CNRN, SCRN, FAHA Disclosures Jeanie Luciano Genentech speakers bureau Claranne Mathiesen - none 1 Objective
More informationThe New Oral Anticoagulants: When and When Not to Use Them Philip C. Comp, M.D., Ph.D. Professor of Medicine, University of Oklahoma Health Sciences
The New Oral Anticoagulants: When and When Not to Use Them Philip C. Comp, M.D., Ph.D. Professor of Medicine, University of Oklahoma Health Sciences Center September 25, 2015 Question: With which of the
More informationAnticoagulation For Atrial Fibrillation
Anticoagulation For Atrial Fibrillation New Agents In A New Era Arjun V Gururaj, MD Arrhythmia and Electrophysiology Nevada Heart and Vascular Center Disclosures Biotronik Speaker Clinical investigator
More informationGRASP-AF Coming to a PCT near you.
GRASP-AF Coming to a PCT near you. ADAS Anticoagulation dosing advisory service Blackpool Teaching Hospitals Trust Sean O'Brien; Anticoagulation Specialist BMS Grasp-AF and the implications on our Anticoagulation
More informationSOUTH EAST WALES CARDIAC NETWORK INTEGRATED CARE PATHWAY CARDIAC REHABILITATION MAY 2005
Name Address SOUTH EAST WALES CARDIAC NETWORK INTEGRATED CARE PATHWAY CARDIAC REHABILITATION MAY 2005 Ms / Miss / Mr / Mrs Addressograph Known as Telephone Number of Birth Hospital No. NHS No. Cardiac
More informationStroke/TIA Interdisciplinary Plan of Care
Stroke/TIA Interdisciplinary Plan of Care Patient/family involved in development of plan of care Patient/family agrees with plan of care Patient unable to be involved in plan of care ER and 1st 24 Hours
More informationPrevention of stroke in patients with atrial fibrillation
www.sign.ac.uk Prevention of stroke in patients with atrial fibrillation A guide for primary care January 2014 Evidence Contents 1 Introduction... 1 2 Detection...2 3 Risk stratification... 3 4 Treatment
More information